Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
53M
-
Shares change
-
+11.1M
-
Total reported value, excl. options
-
$467M
-
Value change
-
+$101M
-
Put/Call ratio
-
0.9
-
Number of buys
-
76
-
Number of sells
-
-46
-
Price
-
$8.80
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2017
174 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q2 2017.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53M shares
of 295M outstanding shares and own 18% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS INC (6.93M shares), BlackRock Inc. (5.62M shares), BAKER BROS. ADVISORS LP (4.11M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (4M shares), VANGUARD GROUP INC (3.47M shares), EcoR1 Capital, LLC (2.57M shares), STATE STREET CORP (1.87M shares), FMR LLC (1.61M shares), Casdin Capital, LLC (1.4M shares), and CITADEL ADVISORS LLC (1.34M shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.